There are 2934 resources available
6572 - CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC)
Presenter: Thomas Yau
Session: Proffered Paper 1 – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Proffered Paper 1 - NSCLC, metastatic - Invited Discussant 1478O and 1479O
Presenter: Lizza Hendriks
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Slides
Webcast
Proffered Paper 1 - NSCLC, metastatic - Invited Discussant LBA79 and LBA80
Presenter: Naiyer Rizvi
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Slides
Webcast
1638 - Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study
Presenter: Fabrice Barlesi
Session: Proffered Paper – CNS tumours
Resources:
Abstract
Slides
Webcast
4648 - Prognostic role of the EANO ESMO classification of leptomeningeal metastases
Presenter: Emilie Le Rhun
Session: Proffered Paper – CNS tumours
Resources:
Abstract
Slides
4361 - A Phase 0/2 Clinical Trial of a CDK4/6 Inhibitor in Aggressive Meningioma Patients
Presenter: Nader Sanai
Session: Proffered Paper – CNS tumours
Resources:
Abstract
Slides
Webcast
1688 - Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients
Presenter: Mario Caccese
Session: Proffered Paper – CNS tumours
Resources:
Abstract
Slides
Webcast
2560 - BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)
Presenter: Nicoletta Colombo
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
6602 - Phase 1B/2 Study of AVB500 (High Affinity Inhibitor of GAS6/AXL Path) in Combination with PAC and PLD in Platinum Resistant Recurrent Ovarian Cancer
Presenter: Bradley Monk
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
1547 - Randomized Phase 2 (RP2) Study of ATR inhibitor M6620 in Combination with Gemcitabine versus Gemcitabine alone in Platinum-Resistant High Grade Serous Ovarian Cancer (HGSOC)
Presenter: Panagiotis Konstantinopoulos
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast